Comparative Pharmacology
Head-to-head clinical analysis: NUFYMCO versus NYSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUFYMCO versus NYSTATIN.
NUFYMCO vs NYSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
Nystatin binds to sterols in the fungal cell membrane, primarily ergosterol, altering membrane permeability and causing leakage of intracellular components, leading to fungal cell death.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
Oral: 500,000 to 1,000,000 units (5-10 mL suspension) swish and swallow 3-4 times daily; Vaginal: 1 vaginal tablet (100,000 units) once or twice daily; Topical: Apply cream/ointment 2-3 times daily; duration depends on indication.
None Documented
None Documented
Clinical Note
moderateNystatin + Tranilast
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast."
Clinical Note
moderateNystatin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic acid."
Clinical Note
moderateNystatin + Nimesulide
"The risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide."
Clinical Note
moderateNystatin + Risedronic acid
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Due to minimal systemic absorption, a terminal elimination half-life is not clinically relevant. In vitro plasma degradation half-life is approximately 1.5 hours, but this is not applicable in vivo.
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Nystatin is not absorbed from the gastrointestinal tract after oral administration; virtually 100% of the ingested dose is excreted unchanged in the feces. After topical application, systemic absorption is negligible; any absorbed drug is excreted via bile and feces (<1% renal).
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Nystatin is combined with Risedronic acid."